Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.62 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.58 |
| ▸ | HPGD | P15428 | 6/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 6/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | CASP7 | P55210 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27878512 | 0.93 | ALDH1A1 (0.65) | ALDH1A1CYP2A6CYP1A2HSD17B10HPGD | |
| SCHEMBL550683 | 0.93 | ALDH1A1 (0.65) | ALDH1A1CYP2A6CYP1A2HSD17B10HPGD | |
| SCHEMBL4647758 | 0.85 | CYP1A2 (0.59) | ALDH1A1CYP2A6CYP1A2HSD17B10HPGD | |
| SCHEMBL598916 | 0.83 | ALDH1A1 (0.60) | ALDH1A1CYP2A6CYP1A2HSD17B10HPGD | |
| SCHEMBL29487823 | 0.83 | HSD17B10 (0.72) | ALDH1A1CYP2A6CYP1A2HSD17B10HPGD | |
| SCHEMBL535472 | 0.83 | HSD17B10 (0.72) | ALDH1A1CYP2A6CYP1A2HSD17B10HPGD | |
| SCHEMBL29613365 | 0.83 | HSD17B10 (0.72) | ALDH1A1CYP2A6CYP1A2HSD17B10HPGD | |
| SCHEMBL18896118 | 0.81 | ALDH1A1 (0.67) | ALDH1A1CYP2A6CYP1A2HSD17B10HPGD | |
| SCHEMBL31137917 | 0.80 | CYP1A2 (0.70) | ALDH1A1CYP2A6CYP1A2HSD17B10HPGD | |
| SCHEMBL18556238 | 0.80 | ALDH1A1 (0.59) | ALDH1A1CYP2A6CYP1A2HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8114997-B2 | N4-acylcytosine nucleosides for treatment of viral infections | PHARMASSET, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-RE42015-E1 | N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections | PHARMASSET, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090176730-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | GILEAD PHARMASSET LLC | 2007-04-05 | — | — | US | disclosed |
| US-7105527-B2 | N4-acylcytosine nucleosides for treatment of viral infections | GILEAD PHARMASSET LLC | 2006-09-12 | — | — | US | disclosed |
| US-6908924-B2 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | PHARMASSET, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20040214844-A1 | N4-acylcytosine nucleosides for treatment of viral infections | GILEAD PHARMASSET LLC | 2004-10-28 | — | — | US | disclosed |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | GILEAD PHARMASSET LLC | 2003-09-18 | — | — | US | disclosed |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | PHARMASSET, INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2003051306-A2 | N4-ACYLCYTOSINE-1,3-DIOXOLANE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | ENTPD5, DUT, NT5C3B | ALDH1A1 2325/4885CYP2A6 1327/4885CYP1A2 1240/4885 |
| US-20090176730-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, NT5C3B, PNP | ALDH1A1 2300/4885CYP2A6 1388/4885CYP1A2 1415/4885 |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | ENTPD5, CDA, ADA | ALDH1A1 645/4885CYP2A6 1101/4885CYP1A2 810/4885 |
| US-20040214844-A1 | N4-acylcytosine nucleosides for treatment of viral infections | ENTPD5, DUT, PNP | ALDH1A1 2002/4885CYP2A6 1193/4885CYP1A2 1161/4885 |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | DERA, DPYD, DHPS | ALDH1A1 14/4885CYP2A6 1024/4885CYP1A2 592/4885 |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, DUT, NT5C3B | ALDH1A1 2341/4885CYP2A6 1296/4885CYP1A2 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.